The implementation plan of the "two-vote system" has been gradually implemented. 25 provinces and cities have officially issued a clear timetable.
The progress of the implementation of the "two-vote system" affects the nerves of the market. Recently, Shanghai, Zhejiang Province, Inner Mongolia and other places introduced the two vote system implementation plan. According to the statistics of Securities Daily, as of July 5, the relevant departments of 25 provinces, autonomous regions and municipalities directly under the central government have officially issued the implementation plan of the two vote system for drug procurement (for Trial Implementation).
"The introduction of the two-vote system will have an impact on pharmaceutical manufacturers, pharmaceutical distribution companies and other entities." A listed company in the pharmaceutical industry previously told the Securities Daily reporter. With this policy change, pharmaceutical circulation enterprises will face integration, and pharmaceutical production enterprises will also face marketing promotion changes in the future.
Two-vote system accelerates deployment
It is understood that the circulation of drugs from manufacturers to patients has to go through layers of price increases, which leads to false high prices of some drugs. In order to rectify the problems in the field of drug circulation, since last year, the national regulatory authorities have adopted multiple measures to implement the two-invoice system (production enterprises issue one invoice to circulation enterprises, and circulation enterprises issue one invoice to medical institutions) to reduce the cost of drug circulation.
To this end, the General Office of the State Council issued the "Several Opinions on Further Reforming and Improving the Policies for the Production, Circulation and Use of Drugs" (hereinafter referred to as the "Opinions"). Focusing on solving outstanding problems in the field of medicine, the opinions put forward systematic reform measures from the whole chain and process of drug production, circulation and use, and clearly proposed to promote the "two vote system" of drug purchase and sale in China by 2018 ".
According to the "Securities Daily" reporter statistics, at present, 25 places have issued a two-vote system implementation plan (trial), a clear timetable. It is understood that many places have set up a transition period of different durations for the implementation of the two-vote system, some areas for 5 months, and some areas for 3 months, allowing drug production and distribution companies and public medical institutions to digest inventory during the transition period., Adjust and reconstruct the drug supply chain system.
For the two-vote system, different regions have given different regulations, among which the identification and implementation steps of the main body of the production enterprises that have attracted the attention of the market also have their own characteristics.
For example, from the perspective of the identification of production enterprises, the recently released "Notice on Printing and Distributing the Implementation Plan of the" Two-Invoice System "for Drug Procurement in Shanghai Public Medical Institutions (Trial)" shows that Shanghai's identification of the two-invoice system is: drug production enterprises Issue an invoice to a circulation enterprise, and a circulation enterprise issue an invoice to a medical institution. Among them, a wholly-owned or holding commercial company (only one commercial company in the country) established by a pharmaceutical manufacturing enterprise or a group-type enterprise integrating science, industry and trade that only sells the drugs of the enterprise (group), and a domestic general agent for overseas drugs (only one domestic general agent in the country) can be regarded as a manufacturing enterprise.
However, the implementation plan of "two vote system" for drug procurement of public medical institutions in Guangxi Zhuang Autonomous Region (for Trial Implementation) further "relaxes" the standards of production enterprises, that is, the production enterprises or operating enterprises (only one enterprise in the whole country) entrusted by drug marketing license holders to be responsible for drug sales can be regarded as production enterprises.
The steps to implement the two-vote system are also different in some regions. For example, it is stipulated in many places that public medical institutions in the province have formally implemented the "two-vote system" in an all-round way, while some regions have launched a gradual promotion model according to local characteristics.
Pharmaceutical industry comprehensive reshuffle
The introduction of the "two-vote system" first had an impact on pharmaceutical distribution enterprises. Analysts believe that the "two-invoice system" will compress the drug circulation link, the pharmaceutical circulation industry will be further integrated, most small and medium-sized uncompetitive commercial enterprises will gradually disappear, and large-scale pharmaceutical circulation enterprises with strong comprehensive competitiveness will obviously benefit.
However, in the view of people in the industry, there are many historical behaviors in the pharmaceutical business field that are characterized as illegal, such as affiliation, ticket passing and false invoicing, which leads to the integration of commercial enterprises that may bear fiscal and tax risks. At present, the integration of commercial enterprises is not as good as expected.
In addition, the impact of this policy on pharmaceutical companies cannot be ignored. Prior to this, Shi Lichen, the founder of the third-party pharmaceutical service platform Maxwell, introduced to reporters that there are currently thousands of pharmaceutical companies in China, but there are not many pharmaceutical companies with self-employed teams. Most companies are still based on the agency model. With the introduction of policies such as the two-vote system, the marketing of pharmaceutical companies without self-employed teams will fall into an unsustainable state.
A person from a listed company in the pharmaceutical industry told reporters that this has increased the operating costs of the company to a certain extent.